Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
35.34
+1.46 (4.31%)
At close: Jul 2, 2026, 4:00 PM EDT
34.78
-0.56 (-1.58%)
After-hours: Jul 2, 2026, 7:50 PM EDT
Neurogene Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
558.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| Arvinas | 89.40M |
| Assembly Biosciences | 71.10M |
| XOMA Royalty | 48.56M |
| Editas Medicine | 38.69M |
| Crescent Biopharma | 11.88M |
| Shattuck Labs | 1.00M |
NGNE News
- 2 days ago - Neurogene prices 3.5M shares at $30.00 in public offering - TheFly
- 2 days ago - Neurogene Inc. Announces Pricing of $125 Million Public Offering - Business Wire
- 2 days ago - Neurogene 75M Spot Secondary; re-offered at $30.00 - TheFly
- 2 days ago - Neurogene announces common stock offering, no amount given - TheFly
- 2 days ago - Neurogene Inc. Announces Proposed Public Offering - Business Wire
- 4 days ago - Neurogene Transcript: Study result - Transcripts
- 4 days ago - Neurogene Press release: Study result - Filings
- 4 days ago - Neurogene Slides: Study result - Filings